BEGIN:VCALENDAR VERSION:2.0 PRODID:-//171.67.215.200//NONSGML kigkonsult.se iCalcreator 2.26.9// CALSCALE:GREGORIAN METHOD:PUBLISH X-FROM-URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar X-WR-TIMEZONE:America/Los_Angeles BEGIN:VTIMEZONE TZID:America/Los_Angeles X-LIC-LOCATION:America/Los_Angeles BEGIN:STANDARD DTSTART:20231105T020000 TZOFFSETFROM:-0700 TZOFFSETTO:-0800 RDATE:20241103T020000 TZNAME:PST END:STANDARD BEGIN:DAYLIGHT DTSTART:20240310T020000 TZOFFSETFROM:-0800 TZOFFSETTO:-0700 RDATE:20250309T020000 TZNAME:PDT END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT UID:ai1ec-2677@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240329T160404Z CATEGORIES;LANGUAGE=en-US:Canary Center CONTACT:Ashley Williams\; ashleylw@stanford.edu\; https://www.earlydetectio nresearch.com/ DESCRIPTION:Cancer Research UK\, OHSU Knight Cancer Institute and the Canar y Center at Stanford\, present the Early Detection of Cancer Conference se ries. The annual Conference brings together experts in early detection fro m multiple disciplines to share ground breaking research and progress in t he field.\nThe Conference is part of a long-term commitment to invest in e arly detection research\, to understand the biology behind early stage can cers\, find new detection and screening methods\, and enhance uptake and a ccuracy of screening.\nThe 2021 conference will take place October 6-8 vir tually. For more information visit the website: http://earlydetectionresea rch.com/\nTickets: https://www.earlydetectionresearch.com/virtual-experien ce/. DTSTART;VALUE=DATE:20211006 DTEND;VALUE=DATE:20211009 LOCATION:Virtual Event SEQUENCE:0 SUMMARY:Early Detection of Cancer Conference URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/early-de tection-of-cancer-conference-2/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/EDx21_300x300-150x150.jpg\;150\;150\;1 \,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-cont ent/uploads/2019/10/EDx21_300x300.jpg\;300\;300\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n
\\nCancer Research UK\, OHSU Knight Cancer Institute and the Canary Center at Stanford\, present the Early Detection of Cancer Conference series. The annual Conference brings together experts in early detection from multiple disciplines to share ground breaking res earch and progress in the field.
\nThe Conference is part of a long- term commitment to invest in early detection research\, to understand the biology behind early stage cancers\, find new detection and screening meth ods\, and enhance uptake and accuracy of screening.
\nThe 20 21 conference will take place October 6-8 virtually. For more information visit the website: http://earlydetectionresearch.com/
\nTickets: https://www.earlydetectionresearch.com/virtual- experience/.
X-TICKETS-URL:https://www.earlydetectionresearch.com/virtual-experience/ END:VEVENT BEGIN:VEVENT UID:ai1ec-1847@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240329T160404Z CATEGORIES;LANGUAGE=en-US:SMAC CONTACT:https://med.stanford.edu/smac/events/2nd-annual-disability-conferen ce.html#registration DESCRIPTION:Date: April 10\, 2021 (8 AM-6PM)\n\n\n\n8 AM-8:20 AM opening re marks Zainub and Pete\n8:20 AM-9:20 AM Talk 1 “I fought the law and no one won”\n\n\n10 minute Break\n9:30 AM-10:30 AM talk 2 students and doctors w ith disabilities panel\n\n\n20 minute break\n\n\n\n\n10:50 AM-11:50 AM Bre akout\nOne hour lunch (TBD)\n12:50 PM-1:50 PM Talk 3 the frontiers of dis ability research \n\n\nLisa Meeks is moderating\nBonnie Swenor invited\n\n 10 minute break\n2:00 PM-3:00 PM breakout 2\n\n\n10 minute break\n3:10 PM- 4:10 PM talk 4 do-it-yourself disability advocacy (Poullos/Tolchin with st udents)\n\n\n4:10 PM-4:30 PM closing remarks\n\n\n4:30 PM-6 PM virtual hap py hour\n\n \n \nTickets: https://med.stanford.edu/smac/events/2nd-annual- disability-conference.html#registration. DTSTART;TZID=America/Los_Angeles:20210410T080000 DTEND;TZID=America/Los_Angeles:20210410T180000 SEQUENCE:0 SUMMARY:Stanford School of Medicine’s 2nd Annual Conference on Disability i n Healthcare and Medicine URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/stanford -school-of-medicines-2nd-annual-conference-on-disability-in-healthcare-and -medicine/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2020/10/Screen-Shot-2021-03-04-at-10.39.22-AM- e1614883544333-150x150.jpeg\;150\;150\;1\,medium\;http://web.stanford.edu/ group/radweb/cgi-bin/radcalendar/wp-content/uploads/2020/10/Screen-Shot-20 21-03-04-at-10.39.22-AM-e1614883544333-300x300.jpeg\;300\;300\;1\,large\;h ttp://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads /2020/10/Screen-Shot-2021-03-04-at-10.39.22-AM-e1614883443684-1024x1024.jp eg\;640\;640\;1\,full\;http://web.stanford.edu/group/radweb/cgi-bin/radcal endar/wp-content/uploads/2020/10/Screen-Shot-2021-03-04-at-10.39.22-AM-e16 14883544333.jpeg\;883\;883\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nDate: April 10\, 2021 (8 AM-6PM)< /span>
\n\n
\n
Tickets: https://med.stanford.edu/smac/events/2nd-an nual-disability-conference.html#registration.
X-TICKETS-URL:https://med.stanford.edu/smac/events/2nd-annual-disability-co nference.html#registration END:VEVENT BEGIN:VEVENT UID:ai1ec-2417@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240329T160404Z CATEGORIES;LANGUAGE=en-US:Canary Center\,IBIIS\,MIPS\,PHIND\,Radiology\,RSL CONTACT:Marta Flory\; flory@stanford.edu DESCRIPTION:Targeted violence continues against Black Americans\, Asian Ame ricans\, and all people of color. The department of radiology diversity co mmittee is running a racial equity challenge to raise awareness of systemi c racism\, implicit bias and related issues. Participants will be provided a list of resources on these topics such as articles\, podcasts\, videos\ , etc.\, from which they can choose\, with the “challenge” of engaging wit h one to three media sources prior to our session (some videos are as shor t as a few minutes). Participants will meet in small-group breakout sessio ns to discuss what they’ve learned and share ideas.\nPlease reach out to M arta Flory\, flory@stanford.edu with questions. For details about the sess ion\, including recommended resources and the Zoom link\, please reach out to Meke Faaoso at mfaaoso@stanford.edu.\nTickets: https://docs.google.com /spreadsheets/d/1ehKqHm32peHcm7NQJ427OaKIa9JpfHVunjBk66etZGc/edit?usp=shar ing. DTSTART;TZID=America/Los_Angeles:20210430T120000 DTEND;TZID=America/Los_Angeles:20210430T130000 LOCATION:Zoom SEQUENCE:0 SUMMARY:Racial Equity Challenge: Race in society URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/racial-e quity-challenge-race-in-society/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2021/04/shield-150x150.png\;150\;150\;1\,mediu m\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/upl oads/2021/04/shield.png\;225\;225\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nTargeted violence continues against Black Ameri cans\, Asian Americans\, and all people of color. The department of radiol ogy diversity committee is running a racial equity challenge to raise awar eness of systemic racism\, implicit bias and related issues. Participants will be provided a list of resources on these topics such as articles\, po dcasts\, videos\, etc.\, from which they can choose\, with the “challenge” of engaging with one to three media sources prior to our session (some vi deos are as short as a few minutes). Participants will meet in small-group breakout sessions to discuss what they’ve learned and share ideas.
\n< p>Please reach out to Marta Flory\, fl ory@stanford.edu with questions. For details about the session\, inclu ding recommended resources and the Zoom link\, please reach out to Meke Fa aoso at mfaaoso@stanford.edu.\n X-TICKETS-URL:https://docs.google.com/spreadsheets/d/1ehKqHm32peHcm7NQJ427O aKIa9JpfHVunjBk66etZGc/edit?usp=sharing END:VEVENT BEGIN:VEVENT UID:ai1ec-1757@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240329T160404Z CATEGORIES;LANGUAGE=en-US:Canary Center\,Early Cancer Detection Seminar Ser ies CONTACT:Ashley Williams\; ashleylw@stanford.edu\; https://canarycenter.stan ford.edu/seminars.html DESCRIPTION:CEDSS: “Building a Scalable Clinical Genomics Program: How tumo r\, normal\, and plasma DNA sequencing are informing cancer care\, cancer risk\, and cancer detection”\n \nMichael Berger\, Ph.D.\nElizabeth and Fel ix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Krav is Center for Molecular Oncology\nMemorial Sloan Kettering Cancer Center\n \nZoom Details\nMeeting URL: https://stanford.zoom.us/s/92559505314\nDial : US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nMeeting ID: 925 595 0 5314\nPasscode: 418727\n11:00am – 12:00pm Seminar & Discussion\nRSVP Her e\n \nABSTRACT\nTumor molecular profiling is a fundamental component of pr ecision oncology\, enabling the identification of oncogenomic mutations th at can be targeted therapeutically. To accelerate enrollment to clinical t rials of molecularly targeted agents and guide treatment selection\, we ha ve established a center-wide\, prospective clinical sequencing program at Memorial Sloan Kettering Cancer Center using a custom\, paired tumor-blood normal sequencing assay (MSK-IMPACT)\, which we have used to profile more than 50\,000 patients with solid tumors. Yet beyond just the characteriza tion of tumor-specific alterations\, the inclusion of blood DNA has readil y enabled the identification of germline risk alleles and somatic mutation s associated with clonal hematopoiesis. To complement this approach\, we h ave also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for cancer detection\, surveillance\, and treatment selection and monitoring. In my talk\, I will describe the prevalence of somatic and germline genomic alte rations in a real-world population\, the clinical benefits of cfDNA assess ment\, and how clonal hematopoiesis can inform cancer risk and confound li quid biopsy approaches to cancer detection.\n \nABOUT\nMichael Berger\, Ph D\, holds the Elizabeth and Felix Rohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Me morial Sloan Kettering Cancer Center\, a multidisciplinary initiative to p romote precision oncology through genomic analysis to guide the diagnosis and treatment of cancer patients. He is also an Associate Attending Geneti cist in the Department of Pathology with expertise in cancer genomics\, co mputational biology\, and high-throughput DNA sequencing technology. His l aboratory is developing experimental and computational methods to characte rize the genetic makeup of individual cancers and identify genomic biomark ers of drug response and resistance. As Scientific Director of Clinical NG S in the Molecular Diagnostics Service\, he oversees the development and b ioinformatics associated with clinical sequencing assays\, and he helped l ead the development and implementation of MSK-IMPACT\, a comprehensive FDA -authorized tumor sequencing panel that been used to profile more than 60\ ,000 tumors from advanced cancer patients at MSK. The resulting data have enabled the characterization of somatic and germline biomarkers across man y cancer types and the identification of mutations associated with clonal hematopoiesis. Dr. Berger also led the development of a clinically validat ed plasma cell-free DNA assay\, MSK-ACCESS\, which his laboratory is using to explore tumor evolution\, acquired drug resistance\, and occult metast atic disease. He received his Bachelor’s Degree in Physics from Princeton University and his Ph.D. in Biophysics from Harvard University.\n \nHosted by: Utkan Demirci\, Ph.D.\nSponsored by: The Canary Center & the Departme nt of Radiology \nStanford University – School of Medicine\nTickets: https ://stanford.zoom.us/webinar/register/5516153318622/WN_MT7TTEciRoWmLVP9GlsJ RA. DTSTART;TZID=America/Los_Angeles:20210511T110000 DTEND;TZID=America/Los_Angeles:20210511T120000 LOCATION:Zoom - See Description for Zoom Link SEQUENCE:0 SUMMARY:Cancer Early Detection Seminar Series – Michael Berger\, Ph.D. URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/cancer-e arly-detection-seminar-series-michael-f-berger-ph-d/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/berger_160204_07-2_3x2-150x150.jpg\;15 0\;150\;1\,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radcalenda r/wp-content/uploads/2019/10/berger_160204_07-2_3x2-300x200.jpg\;300\;200\ ;1\,large\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-con tent/uploads/2019/10/berger_160204_07-2_3x2.jpg\;600\;400\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nCEDSS: “Building a Scalable Clinical Genomics Program: How tumor\, normal\, and plasma DNA se quencing are informing cancer care\, cancer risk\, and cancer detection” em>
\n\n\n
Elizabeth and Fel
ix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Krav
is Center for Molecular Oncology
\nMemorial Sloan Kettering Cancer Ce
nter
\n
Zoom Details
\nMeeti
ng URL: https://stanford.zoom.us/s/92559505314
\nDial: US: +1
650 724 9799 or +1 833 302 1536 (Toll Free)
\nMeeting ID: 925 5950
5314
\nPasscode: 418727
11:00am – 12:00pm Seminar & Discussio
n
\nRSVP Here
\n
ABSTRAC
T
\nTumor molecular profiling is a fundamental component of
precision oncology\, enabling the identification of oncogenomic mutations
that can be targeted therapeutically. To accelerate enrollment to clinical
trials of molecularly targeted agents and guide treatment selection\, we
have established a center-wide\, prospective clinical sequencing program a
t Memorial Sloan Kettering Cancer Center using a custom\, paired tumor-blo
od normal sequencing assay (MSK-IMPACT)\, which we have used to profile mo
re than 50\,000 patients with solid tumors. Yet beyond just the characteri
zation of tumor-specific alterations\, the inclusion of blood DNA has read
ily enabled the identification of germline risk alleles and somatic mutati
ons associated with clonal hematopoiesis. To complement this approach\, we
have also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for canc
er detection\, surveillance\, and treatment selection and monitoring. In m
y talk\, I will describe the prevalence of somatic and germline genomic al
terations in a real-world population\, the clinical benefits of cfDNA asse
ssment\, and how clonal hematopoiesis can inform cancer risk and confound
liquid biopsy approaches to cancer detection.
\n
AB
OUT
\nMichael Berger\, PhD\, holds the Elizabeth and Felix R
ohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kra
vis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Cente
r\, a multidisciplinary initiative to promote precision oncology through g
enomic analysis to guide the diagnosis and treatment of cancer patients. H
e is also an Associate Attending Geneticist in the Department of Pathology
with expertise in cancer genomics\, computational biology\, and high-thro
ughput DNA sequencing technology. His laboratory is developing experimenta
l and computational methods to characterize the genetic makeup of individu
al cancers and identify genomic biomarkers of drug response and resistance
. As Scientific Director of Clinical NGS in the Molecular Diagnostics Serv
ice\, he oversees the development and bioinformatics associated with clini
cal sequencing assays\, and he helped lead the development and implementat
ion of MSK-IMPACT\, a comprehensive FDA-authorized tumor sequencing panel
that been used to profile more than 60\,000 tumors from advanced cancer pa
tients at MSK. The resulting data have enabled the characterization of som
atic and germline biomarkers across many cancer types and the identificati
on of mutations associated with clonal hematopoiesis. Dr. Berger also led
the development of a clinically validated plasma cell-free DNA assay\, MSK
-ACCESS\, which his laboratory is using to explore tumor evolution\, acqui
red drug resistance\, and occult metastatic disease. He received his Bache
lor’s Degree in Physics from Princeton University and his Ph.D. in Biophys
ics from Harvard University.
\n
Hosted by: Utkan Demirc
i\, Ph.D.
\nSponsored by
: The Canary Center & the Department of Radiology
\nStanfor
d University – School of Medicine
Tickets: https://stanford.zoom.us/webinar/registe r/5516153318622/WN_MT7TTEciRoWmLVP9GlsJRA.
X-TICKETS-URL:https://stanford.zoom.us/webinar/register/5516153318622/WN_MT 7TTEciRoWmLVP9GlsJRA END:VEVENT BEGIN:VEVENT UID:ai1ec-2295@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240329T160404Z CATEGORIES;LANGUAGE=en-US:Canary Center\,Early Cancer Detection Seminar Ser ies CONTACT:Ashley Williams\; ashleylw@stanford.edu\; https://canarycenter.stan ford.edu/seminars.html DESCRIPTION:CEDSS: The First Cell: A new model for cancer research and trea tment\nAzra Raza\, M.D.\nChan Soon-Shiong Professor of Medicine\nDirector\ , Myelodysplastic Syndrome Center\nColumbia University Medical Center\n \n Location: Zoom\nMeeting URL: https://stanford.zoom.us/s/99340345860\nDial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nMeeting ID: 993 4034 5860\nPasscode: 711508\nRSVP Here\n \nABSTRACT\nCancer research continues to be predicated on a 1970’s model of research and treatment. Despite hal f a century of intense research\, we are failing spectacularly to improve the outcome for patients with advanced disease. Those who are cured contin ue to be treated mostly with the older strategies (surgery-chemo-radiation ). Our contention is that the real solution to the cancer problem is to di agnose cancer early\, at the stage of The First Cell. The rapidly evolving technologies are doing much in this area but need to be expanded. We stud y a pre-leukemic condition called myelodysplastic syndrome (MDS) with the hope that we can detect the first leukemia cells as the disease transforms to acute myeloid leukemia (AML). Towards this end\, we have collected blo od and bone marrow samples on MDS and AML patients since 1984. Today\, our Tissue Repository has more than 60\,000 samples. We propose novel methods to identify surrogate markers that can identify the First Cell through st udying the serial samples of patients who evolve from MDS to AML.\n \nABOU T\nDr. Raza is a Professor of Medicine and Director of the MDS Center at C olumbia University in New York\, NY.She started her research in Myelodispl astic Syndromes (MDS) in 1982 and moved to Rush University\, Chicago\, Ill inois in 1992\, where she was the Charles Arthur Weaver Professor in Oncol ogy and Director\, Division of Myeloid Diseases. The MDS Program\, along w ith a Tissue Repository containing more than 50\,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Ma ssachusetts in 2004 and to Columbia University in 2010.\nBefore moving to New York\, Dr. Raza was the Chief of Hematology Oncology and the Gladys Sm ith Martin Professor of Oncology at the University of Massachussetts in Wo rcester. She has published the results of her laboratory research and clin ical trials in prestigious\, peer reviewed journals such as The New Englan d Journal of Medicine\, Nature\, Blood\, Cancer\, Cancer Research\, Britis h Journal of Hematology\, Leukemia\, and Leukemia Research. Dr. Raza serve s on numerous national and international panels as a reviewer\, consultant and advisor and is the recipient of a number of awards.\n \nHosted by: Ut kan Demirci\, Ph.D.\nSponsored by: The Canary Center & the Department of R adiology \nStanford University – School of Medicine DTSTART;TZID=America/Los_Angeles:20211012T110000 DTEND;TZID=America/Los_Angeles:20211012T120000 LOCATION:Venue coming soon! SEQUENCE:0 SUMMARY:Cancer Early Detection Seminar Series – Azra Raza\, MD URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/cancer-e arly-detection-seminar-series-azra-raza-md/ X-COST-TYPE:free X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/A_Raza-150x150.png\;150\;150\;1\,mediu m\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/upl oads/2019/10/A_Raza-300x200.png\;300\;200\;1\,large\;http://web.stanford.e du/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/A_Raza.png\ ;640\;426\;\,full\;http://web.stanford.edu/group/radweb/cgi-bin/radcalenda r/wp-content/uploads/2019/10/A_Raza.png\;700\;466\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nCEDSS: The First Cell: A new model for cancer research and treatment
\nAzra Raza\, M.D.
\nChan
Soon-Shiong Professor of Medicine
\nDirector\, Myelodysplastic Syndro
me Center
\nColumbia University Medical Center
\n
L
ocation: Zoom
\nMeeting URL: https:
//stanford.zoom.us/s/99340345860
\nDial: US: +1 650 724 9799 or
+1 833 302 1536 (Toll Free)
\nMeeting ID: 993 4034 5860
\nPassco
de: 711508
ABSTRACT
\nCancer research continues to be predicated on a 1970’s model of research and treatment. Despite half a century of intense research\, we are failing spectacularly to improve the outcome for patients with advanced disease. Those who are cured continue to be treated mostly with the older strategies (surgery-chemo-radiation). Our contention is that the real solution to the cancer problem is to diagn ose cancer early\, at the stage of The First Cell. The rapidly evolving te chnologies are doing much in this area but need to be expanded. We study a pre-leukemic condition called myelodysplastic syndrome (MDS) with the hop e that we can detect the first leukemia cells as the disease transforms to acute myeloid leukemia (AML). Towards this end\, we have collected blood and bone marrow samples on MDS and AML patients since 1984. Today\, our Ti ssue Repository has more than 60\,000 samples. We propose novel methods to identify surrogate markers that can identify the First Cell through study ing the serial samples of patients who evolve from MDS to AML.
\np>\n
ABOUT
\nDr. Raza is a Professor of Medicine and Director of the MDS Center at Columbia University in New York\, NY.She started her research in Myelodisplastic Syndromes (MDS) in 1982 and moved to Rush University\, Chicago\, Illinois in 1992\, where she was the Charl es Arthur Weaver Professor in Oncology and Director\, Division of Myeloid Diseases. The MDS Program\, along with a Tissue Repository containing more than 50\,000 samples from MDS and acute leukemia patients was successfull y relocated to the University of Massachusetts in 2004 and to Columbia Uni versity in 2010.
\nBefore moving to New York\, Dr. Raza was the Chie f of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachussetts in Worcester. She has published the r esults of her laboratory research and clinical trials in prestigious\, pee r reviewed journals such as The New England Journal of Medicine\, Nature\, Blood\, Cancer\, Cancer Research\, British Journal of Hematology\, Leukem ia\, and Leukemia Research. Dr. Raza serves on numerous national and inter national panels as a reviewer\, consultant and advisor and is the recipien t of a number of awards.
\n\n
Hosted by: Utkan Demirci\,
Ph.D.
\nSponsored by: Th
e Canary Center & the Department of Radiology
\nStanford Un
iversity – School of Medicine
Alone in the Ring (a research-based theatre production about inclusive healthcare workplaces) is coming to ca mpus during the Annual Stanford School of Medicine Diversity Week and Nati onal Disability Employment Awareness Month\, SMAC and Stanford Medicine and the Muse hope to continue the discussion on how to spark and sustain change towards inclusive workspaces. Alone in the Ring is followed by a discussio n between the team and audience members. During the presentation\, audienc e members are encouraged to reflect: How inclusive is your workspace? How could you make it more accessible?
\n\n END:VEVENT BEGIN:VEVENT UID:ai1ec-3015@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240329T160404Z CATEGORIES;LANGUAGE=en-US:SMAC CONTACT:https://med.stanford.edu/facultydiversity/faculty-community/network s/heal-network.html DESCRIPTION:Office of Faculty Development and Diversity and SMAC.\nThe OFDD team welcomes all Stanford community members to join our inaugural Health Equity Action Leadership (HEAL Network) event\, Health Equity Research in the Latinx Community\, where faculty who do this work will share their ex periences in a fireside chat panel.\nModerator: Lisa Goldman-Rosas\nSpeake rs: Dr. Ken Sutha\, Dr. Peter Poullos\, Dr. Holly Tabor DTSTART;TZID=America/Los_Angeles:20211026T120000 DTEND;TZID=America/Los_Angeles:20211026T130000 SEQUENCE:0 SUMMARY:Health Equity Action Leadership (HEAL Network) Fireside Chat URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/health-e quity-action-leadership-heal-network-fireside-chat/ X-COST-TYPE:free X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2021/09/Screen-Shot-2021-09-16-at-11.21.47-AM- 150x150.png\;150\;150\;1\,medium\;http://web.stanford.edu/group/radweb/cgi -bin/radcalendar/wp-content/uploads/2021/09/Screen-Shot-2021-09-16-at-11.2 1.47-AM-300x191.png\;300\;191\;1\,large\;http://web.stanford.edu/group/rad web/cgi-bin/radcalendar/wp-content/uploads/2021/09/Screen-Shot-2021-09-16- at-11.21.47-AM.png\;596\;379\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nOffice of Faculty Development and Diversity and SMAC.
\nThe OFDD team welcomes all Stanford community members t o join our inaugural Health Equity Action Leadership (HEAL Network) event\, Hea lth Equity Research in the Latinx Community\, where faculty who do this wo rk will share their experiences in a fireside chat panel.
\nModerato r: Lisa Goldman-Rosas
\nSpeakers: Dr. Ken Sutha\, Dr. Peter Poullos\ , Dr. Holly Tabor
\n